| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/21/2009 | CN101347523A Microsphere for injuecting 'Shuang Hualian' for treating viral disease of bird and preparation thereof |
| 01/21/2009 | CN101347522A Nano 'Shuang Hualian' injection preparation for fowl and preparation thereof |
| 01/21/2009 | CN101347512A Macleaya cordata injection and preparation thereof |
| 01/21/2009 | CN101347481A Wild chrysanthemum in situ forming eye gel |
| 01/21/2009 | CN101347455A Carbon-encapsulated iron nanoparticles and use thereof as vector of medicament for treating liver cancer |
| 01/21/2009 | CN101347450A Chondroitin sulfate in situ forming eye gel |
| 01/21/2009 | CN101347449A Constituent of sperm-blocking agent with contraceptive effect |
| 01/21/2009 | CN101347448A Dextran in situ forming eye gel |
| 01/21/2009 | CN101347447A Hypromellose in situ forming eye gel |
| 01/21/2009 | CN101347446A Medicament composition containing astragalus polysaccharide and ginseng bud saponin and uses thereof |
| 01/21/2009 | CN101347444A Compound naphazoline hydrochloride in situ forming eye gel |
| 01/21/2009 | CN101347443A Vitamin B12 in situ forming eye gel |
| 01/21/2009 | CN101347439A Medicament for treating inflammatory bowel disease |
| 01/21/2009 | CN101347437A Medicament composition for treating respiratory disease |
| 01/21/2009 | CN101347436A Uses of methylprednisolone and derivatives thereof in preparing medicament for treating allergic rhinitis |
| 01/21/2009 | CN101347429A Stable tartaric acid ifenprodil injection and method of preparing the same |
| 01/21/2009 | CN101347420A Alficetin soft capsules |
| 01/21/2009 | CN101347414A Divisible galenical preparation form capable of controlling release of active ingredient |
| 01/21/2009 | CN101347410A Anticancer sustained-release injection containing octadecyl dimethyl-4-piperidine phosphate |
| 01/21/2009 | CN101347409A Sustained-release injection containing octadecyl dimethyl-4-piperidine phosphate |
| 01/21/2009 | CN101347406A Injection with high-content praziquantel and method of preparing the same |
| 01/21/2009 | CN101347403A Method for preparing organic metal compound anti-cancer medicine with electrostatic spinning technique |
| 01/21/2009 | CN100453528C Non-symmetrical gelling agent |
| 01/21/2009 | CN100453119C Preparing process of bioadhesive chitosan particle for embedding and transferring active medicine |
| 01/21/2009 | CN100453115C Self-emulsifying agglomerant of oral polypeptide medicine |
| 01/21/2009 | CN100453086C Gel for removing ocular by ice pearl and its preparation |
| 01/21/2009 | CN100453079C Water-soluble liquid internal medicine |
| 01/21/2009 | CN100453078C Method for treating primary insomnia |
| 01/21/2009 | CN100453077C Injectable micelle prepn containing garcinolic acid and its prepn process |
| 01/21/2009 | CN100453069C Biphenyl diester emulsion and its preparing method |
| 01/21/2009 | CN100453068C Injection containing caderfloxacin lactate |
| 01/21/2009 | CN100453067C Preparation of injectable suspensions having improved injectabity |
| 01/21/2009 | CN100453066C Drug delivery system using subconjunctival depot |
| 01/21/2009 | CN100452984C Aimal growth regulating composition and its prepn and use |
| 01/20/2009 | US7479573 Cationic lipids capable of facilitating transport of biologically active agents or substances into cells; lipid aggregate macromolecular complex interacts with cells making the polyanionic macromolecule available for absorption and uptake by the cell |
| 01/20/2009 | US7479552 Type-1 ribosome-inactivating protein |
| 01/20/2009 | US7479546 Pro104 antibody compositions and methods of use |
| 01/20/2009 | US7479535 Star polymer such as of a polylactone based on a central phosphorus atom derived from phosphorus oxychloride (POCl3) or ethyl dichlorophosphate; biodegradable and/or biocompatible; sustained release drug delivery; reverse thermal gelation |
| 01/20/2009 | US7479508 Nimesulide containing topical pharmaceutical compositions |
| 01/20/2009 | US7479503 Such as multiple sclerosis; also inactivating HIV virus via extracorporeal treatment of blood; use of a green porphyrin or porfimer sodium |
| 01/20/2009 | US7479490 pellets comprising resazurin, anhydrous sodium sulfate, 1-hydroxyethylidene biphosphonate, tetrasodium salt and magnesium stearate |
| 01/20/2009 | US7479376 Using caudal-1 gene (CDX-1) as diagnostic indicator of stomach or esophageal cancer; immunodiagnostics |
| 01/20/2009 | US7479285 Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
| 01/20/2009 | US7479280 Papilloma virus capsid support comprising chimeric lymphocyte epitope for use in identifying modulators to treat and prevention cell proiferative, autoimmune and viral diseases |
| 01/20/2009 | US7479276 Antibody fragment-targeted immunoliposomes for systemic gene delivery |
| 01/20/2009 | US7479266 Polyvalent conjugate vaccine for cancer |
| 01/20/2009 | US7479132 An ionic medicine impregnated into an electrode-free ion-exchange membrane having a surface roughness (Rz) of 1 mu m or less; no application of voltage |
| 01/20/2009 | CA2586146C Fluorocarbon aerosol medicaments |
| 01/20/2009 | CA2567575C Organo-gel formulations for therapeutic applications |
| 01/20/2009 | CA2528493C Medicinal composition containing triazole compound |
| 01/20/2009 | CA2488651C System and process for releasing encapsulated active ingredients |
| 01/20/2009 | CA2468916C A stable oxaliplatin solution formulation |
| 01/20/2009 | CA2445519C Method for manufacturing a low dose pharmaceutical composition |
| 01/20/2009 | CA2444116C Pharmaceutical dosage form of amorphous nelfinavir mesylate |
| 01/20/2009 | CA2411685C Optimised pellet formulations |
| 01/20/2009 | CA2392721C Intervertebral disc treatment devices and methods |
| 01/20/2009 | CA2391613C Injection-moulded water-soluble container |
| 01/20/2009 | CA2383916C Dispersion formulations containing lipase inhibitors |
| 01/20/2009 | CA2352762C Oral transmucosal delivery |
| 01/20/2009 | CA2352483C Pharmaceutical aerosol composition containing hfa 227 and hfa 134a |
| 01/20/2009 | CA2352389C An oral formulation for gastrointestinal drug delivery |
| 01/20/2009 | CA2348759C Gel compositions |
| 01/20/2009 | CA2339193C Pharmaceutical compositions comprising ibuprofen and domperidone |
| 01/20/2009 | CA2338794C New oral formulation for 5-ht4 agonists or antagonists |
| 01/20/2009 | CA2312795C The use of phospholipid complexes of extracts of vitis vinifera as anti-atherosclerotic agents |
| 01/20/2009 | CA2305621C Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| 01/20/2009 | CA2247103C Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances |
| 01/20/2009 | CA2246344C A solid non-effervescent compressed dosage form containing racemic ibuprofen |
| 01/20/2009 | CA2213660C Aerosol containing beclamethasone nanoparticle dispersions |
| 01/20/2009 | CA2137822C Method for detecting pre-cancerous or cancerous cells using p90 antibodies or probes |
| 01/18/2009 | CA2598948A1 Enhanced formulations of lamotrigine |
| 01/15/2009 | WO2009009562A2 Glp-1-fc fusion protein formulation |
| 01/15/2009 | WO2009009552A2 Preserving secondary peptide structure |
| 01/15/2009 | WO2009009135A1 Compositions for delivering a drug |
| 01/15/2009 | WO2009009134A1 Compositions for delivering a drug |
| 01/15/2009 | WO2009008727A2 Molecules for targeting compounds to various selected organs or tissues |
| 01/15/2009 | WO2009008725A2 Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| 01/15/2009 | WO2009008595A1 Pharmaceutical liquid composition of botulinum toxin with improved stability |
| 01/15/2009 | WO2009008487A1 Coated preparation |
| 01/15/2009 | WO2009007622A2 Dermatological composition containing calcitriol lipidic vesicles, method for preparing same and use thereof |
| 01/15/2009 | WO2009007376A1 Pharmaceutical compositions for peroral administration of phenothiazine dyestuffs |
| 01/15/2009 | WO2009007137A2 Pharmaceutical composition for topical application of poorly soluble compounds |
| 01/15/2009 | WO2009006898A1 Stable medicated chewing gum comprising cyclodextrin inclusion complex |
| 01/15/2009 | WO2009006799A1 A pharmaceutical compositon comprising taxanes, the preparation and use thereof |
| 01/15/2009 | WO2009006787A1 Composition comprising rotigotine, its use and transdermal patch comprising the composition |
| 01/15/2009 | WO2008116913A3 Peptide compounds with transient biodegradable pegylation |
| 01/15/2009 | WO2008109031A3 Liposome carriers for in vivo delivery of fullerenes |
| 01/15/2009 | WO2008087190A3 Use of peptides in combination with surgical intervention for the treatment of obesity |
| 01/15/2009 | WO2008043366A3 Three-domain compounds for transmembrane delivery |
| 01/15/2009 | WO2007119028A9 Composition including at least one aqueous phase and at least one fatty phase including ivermectin |
| 01/15/2009 | WO2005087199A3 Stabilised supersaturated solid solutions of steroidal drugs |
| 01/15/2009 | US20090018313 Using trisodium citrate wash as tool in recovering fibrinogin from cryo-solution; preparing fibrin fabric for use in surgery and as wound healing agent |
| 01/15/2009 | US20090018218 METHODS OF MODIFYING AMYLOID beta OLIGOMERS USING NON-PEPTIDIC COMPOUNDS |
| 01/15/2009 | US20090018217 Volatile sulfide production inhibitor and method for inhibiting the production of volatile sulfide using the inhibitor |
| 01/15/2009 | US20090018216 Polymer micelle complex including nucleic acid |
| 01/15/2009 | US20090018214 Composition for Promoting Vascular Smooth Muscle Relaxation |
| 01/15/2009 | US20090018208 Novel Succinate Salt of O-Desmethyl-Venlafaxine |
| 01/15/2009 | US20090018190 Compositions and Methods for Transdermal Oxybutynin Therapy |
| 01/15/2009 | US20090018185 Compositions and products containing s-equol, and methods for their making |
| 01/15/2009 | US20090018175 Pharmaceutical excipient complex |